In hepatocellular carcinoma, BMSC-derived EVs modified with GRP7-siRNA have sensitized cells to sorafenib, which, when combined with si-GRP78-modified BMSC-derived EVs, has shown to inhibit the growth and invasion of hepatocellular carcinoma cells in vitro (Figure 6C-D) 131. Here, HSPA5 is linked to hepatocellular carcinoma.